Manufacture of an otic suspension for canine and feline Malassezia otitis externa begins with a micronized miconazole nitrate fraction having a laser diffraction D90 below 15 µm and residual moisture below 0.5% w/w after vacuum drying. The registered in-use concentration in one fixed-dose otic suspension is 23 mg/mL miconazole nitrate, corresponding to 2.3% w/w in a vehicle with density close to 1.0 g/cm³; industrial development bands typically extend from 1.8% w/w to 2.5% w/w to offset potency loss during high-shear processing. The non-aqueous vehicle consists of medium-chain triglycerides, propylene glycol, and a poloxamer wetting agent; the suspending process is carried out under nitrogen blanketing to limit oxidative colour shifts in unsaturated triglycerides. High-shear dispersion uses a toothed colloid mill with rotor-stator gap 50–150 µm, followed by a batch homogeniser operating at 6,000–10,000 rpm for 30–60 min to deflocculate the API. A recurrent production-scale failure mode is the settlement of miconazole nitrate in the transfer line between the colloid mill and the holding tank when line velocity drops below 0.5 m/s; this causes first-fill assay values below release specification and requires recirculation or in-line homogenisation before filling. Release testing applies Ph. Eur. 2.6.12 and Ph. Eur. 2.6.13 for non-sterile cutaneous preparations, Ph. Eur. 2.9.5 for viscosity, and Ph. Eur. 2.9.31 for particle-size distribution by laser diffraction. The manufacturing stream follows EU GMP Volume 4 Part 1 as applied to veterinary medicinal products. Finished presentations include HDPE dropper bottles, metering pump bottles, and single-dose otic squeeze tubes for dogs and cats under veterinary prescription. Incompatibility with strongly alkaline buffers above pH 7.5 must be avoided because miconazole nitrate precipitates as free base crystals; the formulation should not be combined with anionic surfactants at concentrations that displace the poloxamer stabilizer.

When Aqueous Rinse Systems Require a Preserved, Low-Viscosity Vehicle

In chronic otitis externa with biofilm-producing bacteria and secondary Malassezia colonisation, aqueous otic rinse systems are formulated at miconazole nitrate concentrations of 0.7–1.5% w/w to prevent excessive cerumen after cleaning while maintaining a low-viscosity, drainable product. The solvent system uses propylene glycol at 15–30% w/w and a citrate buffer adjusted to pH 3.8–4.4; the low pH maintains the protonated miconazole species in solution and contributes to preservative activity against Pseudomonas aeruginosa. The manufacturing process is a cold dissolution and filtration line: miconazole nitrate is dispersed in propylene glycol under a propeller agitator at 300–500 rpm, buffer is added under stirring, and the bulk is passed through a 5 µm polypropylene cartridge filter before filling into LDPE dropper bottles. Compliance for non-sterile otic liquids is based on Ph. Eur. 5.1.4 category 2, with total aerobic microbial count ≤10² CFU/g, total yeast and mould count ≤10¹ CFU/g, and absence of Staphylococcus aureus and Pseudomonas aeruginosa per Ph. Eur. 2.6.13. Terminal presentations are rinse bottles, unit-dose pipettes, and saturated ear wipes intended for adjunct cleaning before application of a primary otic suspension.

Drinking-water granules are produced from a fluid-bed granulation step in which miconazole nitrate at 2.5–5.0% w/w is dispersed in a lactose-povidone matrix, with crospovidone and anhydrous citric acid added where effervescent dispersion is specified. The granulation step is performed in a top-spray fluid-bed dryer with inlet air temperature 50–65°C, atomizing air pressure 1.5–2.5 bar, and final product moisture below 2.0% w/w; granules are screened to 200–800 µm to avoid segregation and to ensure rapid wetting. Water dispersibility is tested by adding a unit dose to tap water at 25°C under 100 rpm paddle stirring; the target is complete dispersion within 3 min with no visible agglomerates. The process must control the polymorphic form of miconazole nitrate because over-drying above 70°C can reduce dissolution and increase the amorphous fraction; in-process Raman spectroscopy is used on three consecutive batches to verify crystal habit. Compliance includes Ph. Eur. 2.9.3 dissolution testing, Ph. Eur. 2.9.1 disintegration where tablets are compressed, Ph. Eur. 2.6.12/2.6.13, and residual solvent limits under VICH GL18 for the granulation solvent. Finished forms include water-dispersible sachets, bulk farm packs for proportional dosing pumps, and dry powders for reconstitution into oral syrups in multi-species veterinary practice. A production bottleneck occurs when changing from a lactose-based to a sorbitol-based carrier because the hygroscopicity of sorbitol raises moisture uptake to more than 1.5% within 4 h at 60% RH, causing granule agglomeration inside the dryer discharge chute; the discharge environment must therefore be kept below 40% RH for sorbitol-containing batches.

What Limits Dose Uniformity in Low-Dose Tablets and Capsules?

When low-dose oral solid dosage forms are required for companion animal indications, miconazole nitrate is formulated at 50–200 mg per tablet or capsule, with the lower end used for cats and small dogs and the upper end for large dogs or registered multi-day regimens. In the granulate, miconazole nitrate typically represents 2.5–10.0% w/w of the core depending on dose and final tablet mass. Direct compression is generally unsuitable because micronized miconazole nitrate has poor flow and low bulk density; wet granulation with lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, and povidone K30 is preferred, followed by compression to hardness 60–120 N and friability below 0.5% per Ph. Eur. 2.9.7. Dose uniformity is the main compliance risk: for low-dose mini-tablets below 100 mg total mass, coefficient of variation of miconazole content must meet Ph. Eur. 2.9.40 acceptance value; this is achieved by granule particle-size control to D50 150–250 µm and by maintaining relative humidity below 45% during compression to prevent sticking. Disintegration time is targeted at ≤15 min in 0.1 N HCl per Ph. Eur. 2.9.1, and dissolution testing per Ph. Eur. 2.9.3 uses a validated HPLC method with UV detection at 230 nm. Finished products include film-coated tablets, hard gelatin capsules, and mini-tablets for small-animal dosing. Published data for specific veterinary mini-tablet formulations is limited; manufacturers should verify the dissolution profile against the registered reference product in the target species.

Sterile Parenteral Compounding and Terminal Sterilisation Constraints

Injectable presentations of miconazole are formulated at 10 mg/mL miconazole base in an acidified aqueous system containing propylene glycol 10–30% w/w and a preservative-free or benzyl alcohol-containing vehicle, adjusted to pH 3.0–4.0 with hydrochloric acid. Miconazole nitrate is sparingly soluble in plain water; simple aqueous dilution without pH control or cosolvent results in visible precipitation of the free base above pH 6.0. The compounding stream uses aseptic filtration through a 0.22 µm sterilising-grade membrane under nitrogen pressure, followed by filling in glass vials or polypropylene ampoules in an isolator with Grade A air classification. Terminal moist-heat sterilisation at 121°C for 15 min is generally not used for unbuffered acidic solutions because of hydrolysis and discolouration risk; when a terminal sterilisation cycle is unavoidable, it must be bracketed by stability studies. Compliance tests include Ph. Eur. 2.6.1 sterility, Ph. Eur. 2.6.14 bacterial endotoxins, Ph. Eur. 2.9.19 particulate contamination, and USP Chapter 85 where the dossier is harmonized with US requirements. Finished presentations are single-dose vials, ampoules, and concentrated solutions for slow intravenous infusion after dilution; contact surfaces should be polyolefin or glass because adsorption of miconazole onto flexible PVC infusion containers has been reported for related azole systems, and published data for specific veterinary infusion sets is limited.

Premix Homogeneity Loss During Feed-Mill Geometric Dilution

At feed-mill scale, the blending of miconazole-containing premixes is performed as an intermediate step for subsequent dilution into final feed or drinking-water administration where national regulations permit. The premix concentration is typically 5.0–25.0% w/w miconazole nitrate on a lactose monohydrate or corn starch carrier adjusted to D50 100–200 µm, with fumed silica at 0.2–0.5% w/w added as an anti-caking agent. The blending train uses stepwise geometric dilution in a double-cone or V-type blender filled to 65–75% of working volume; mixing time is established by content uniformity sampling at six positions, with acceptance of miconazole assay relative standard deviation below 5%. Electrostatic adhesion of micronized API to the blender walls and discharge chute is a common source of assay drift; bonding with a grounding clamp and maintaining ambient relative humidity between 40–60% reduces the loss to below 0.1% of nominal potency. Compliance is governed by EU Regulation 2019/4 on veterinary medicinal products in medicated feed and EU Regulation 183/2005 for feed hygiene, with analytical verification by HPLC against a validated in-house method. Terminal product types include intermediate premix for registered feed manufacturers, in-feed powders for licensed veterinary use, and sachet premix for on-farm mixing. The operational boundary is that premix containing hygroscopic carriers must not be stored overnight in open hoppers at relative humidity above 60%; moisture absorption above 5% causes caking and invalidates the content uniformity data obtained during release.